FDA granted Orphan Drug Designation to Reolysin, developed by Oncolytics Biotech Inc., for the treatment of ovarian cancer.
Merck and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of Erbitux (cetuximab) to Merck in Japan as of May 1.
NORTHWESTERN UNIVERSITY's Robert H. Lurie Comprehensive Cancer Center, in collaboration with the Northwestern Medicine Developmental Therapeutics Institute and Northwestern Memorial Hospital, has launched a new research program, Northwestern Onco-SET, to provide a personalized, precision medicine option.
NCI will implement President Barack Obama's directive to ramp up the initiative in precision medicine, even if Congress doesn't appropriate specific funds for this purpose, Institute Director Harold Varmus told members of the National Cancer Advisory Board Feb. 12.
DOUGLAS LOWY received the second annual Harrington Prize for Innovation in Medicine from the Harrington Discovery Institute and the American Society for Clinical Investigation.
WILLIAM NELSON will serve as the editor-in-chief of Cancer Today, the American Association for Cancer Research's consumer magazine.
ELI LILLY AND COMPANY announced a commitment of $1 million to AMPATH in Eldoret, Kenya, provided by the Lilly Foundation. The funding, in conjunction with World Cancer Day, will help equip a new oncology center, hire additional staff and train local healthcare professionals.
CAROLYN COMPTON will lead the scientific advisory board of Indivumed GmbH.
THOMAS RUTHERFORD was named network physician director of cancer services for the Western Connecticut Health Network.
FDA granted a second breakthrough designation to the immunotherapy MPDL3280A (anti-PDL1).
